FDA Approves First New Sunscreen Ingredient in 27 Years, Closing the US Protection Gap

For the first time in more than a quarter-century, American consumers are getting a fundamentally new way to protect their skin from the sun. On June 9, the U.S. Food and Drug Administration finalized the approval of bemotrizinol, a highly effective ultraviolet filter, for use in over-the-counter sunscreens. The landmark decision ends a 27-year drought of sunscreen innovation in the United States, bringing the domestic market in line with Europe and Asia, where the ingredient has been a staple since 1999.[2]

The approval of bemotrizinol—often referred to as BEMT or by its trade name, Parsol Shield—solves a long-standing dilemma for American beachgoers and skincare enthusiasts. Until now, U.S. consumers had to choose between chemical filters like avobenzone, which can degrade in sunlight and absorb into the bloodstream, or mineral blockers like zinc oxide, which are stable but notoriously leave a chalky, white cast on the skin. BEMT bridges this gap by offering broad-spectrum protection against both UVA and UVB rays without the greasy texture or ghostly residue.[1]

Public health advocates are celebrating the milestone as a major victory for skin cancer prevention. The Environmental Working Group has spent years pressuring the FDA to modernize its approved ingredient list, noting that traditional U.S. chemical sunscreens routinely fail to shield against the deep-penetrating UVA rays responsible for premature aging and melanoma. By closing this UVA protection gap, bemotrizinol provides a much safer and more comprehensive shield against the sun's most dangerous radiation.[1][3]

The safety profile of bemotrizinol was a critical factor in the FDA’s final decision. Rigorous testing demonstrated that at concentrations up to 6 percent, the large BEMT molecule is minimally absorbed through the skin, keeping it safely out of the bloodstream. The agency's review also confirmed a low risk of skin irritation and sensitization, officially designating the ingredient as generally recognized as safe and effective for adults and children six months and older.

The regulatory journey to this point has been notoriously arduous. Because the FDA classifies sunscreens as over-the-counter drugs rather than cosmetics, new active ingredients must clear the same high hurdles as cold medicines or pain relievers. The original application for BEMT was filed in 2005 under a regulatory framework that has since been discontinued. It wasn't until Congress passed the CARES Act in 2020, which streamlined the over-the-counter monograph process, that a viable path forward finally emerged.[2]

Pushing the ingredient across the finish line required a massive financial and scientific commitment. Dutch manufacturer DSM-Firmenich spent years and an estimated $20 million generating the specific toxicology and absorption data demanded by the FDA. Their perseverance makes bemotrizinol the very first ingredient to successfully navigate the updated regulatory pathway, setting a precedent that the beauty industry hopes will open the door for other modern filters currently trapped in regulatory limbo.

For cosmetic chemists, the introduction of BEMT is a game-changer that will fundamentally alter how American sunscreens feel. Because the ingredient is highly photostable and performs effectively at lower concentrations, formulators can reduce the total percentage of chemical filters in a bottle. This flexibility allows for the creation of elegant, lightweight serums and lotions that absorb quickly, a stark contrast to the thick, heavy creams that currently dominate U.S. pharmacy shelves.[3]

Dermatologists are particularly optimistic about what this sensory improvement means for public health. Currently, only about 13 percent of American adults apply sunscreen on a daily basis, with many citing the unpleasant texture, greasiness, or white cast as primary deterrents. By offering a product that feels more like a high-end moisturizer than a chore, medical professionals hope to drive up daily compliance, which remains the single most effective intervention for preventing skin cancer.

Consumers eager to try the new formulations won't have to wait long. DSM-Firmenich plans to launch BEMT under the Parsol Shield brand later this year. The company holds an 18-month exclusivity window, after which other manufacturers will be free to incorporate the filter into their own product lines. When shopping, consumers should look for bemotrizinol or BEMT on the active ingredients panel, signaling the arrival of a new era in American sun care.[1][2]